Forest Expects Lexapro To Gain Share In Flat Antidepressant Market
This article was originally published in The Pink Sheet Daily
Executive Summary
The company projects escitalopram total Rx share will increase from 19.7% to 21.5% in the next 12 months while the antidepressant market will be down 0.5% for the same period. Lexapro market share has seen a "modest boost" as a result of FDA's seizure of GSK's Paxil CR.